Opus Genetics, INC 10-Q quarterly reports

Opus Genetics reports substantial cash reserves and progress in gene therapy trials, alongside significant financing activities and continued operational losses.

Opus Genetics reports a significant increase in R&D expenses for its inherited retinal disease pipeline, alongside a substantial swing in warrant liability fair value, impacting net loss for the first quarter of 2026.

Opus Genetics reported a significantly wider net loss in Q3 2025, driven by warrant liability changes and increased R&D for gene therapies, while securing new capital to advance its pipeline.

Opus Genetics reports increased cash reserves and significant progress in its gene therapy pipeline, despite rising operating expenses and continued net losses.

Opus Genetics reports its financial results for the first quarter of 2025, highlighting revenue from the Viatris license agreement and progress in its gene therapy programs.

Opus Genetics, formerly Ocuphire Pharma, has completed a merger, shifting its focus to gene therapies for inherited retinal diseases while advancing its existing ophthalmic programs.

Ocuphire Pharma reports a net loss of $14.9 million for the first six months of 2024, while continuing to advance its pipeline of ophthalmic therapies.

Ocuphire Pharma reported a net loss of $7.1 million for the first quarter of 2024, while highlighting progress in its clinical programs and commercialization efforts.